Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Baenas, Isabel
• dc.contributor.author Miranda-Olivos, Romina
• dc.contributor.author Granero, Roser
• dc.contributor.author Solé Morata, Neus, 1988-
• dc.contributor.author Sánchez, Isabel
• dc.contributor.author Pastor, Antonio
• dc.contributor.author Pino-Gutiérrez, Amparo del
• dc.contributor.author Codina, Ester
• dc.contributor.author Tinahones Madueño, Francisco José
• dc.contributor.author Fernández-Formoso, José A.
• dc.contributor.author Vilarrasa, Nuria
• dc.contributor.author Guerrero-Pérez, Fernando
• dc.contributor.author Lopez-Urdiales, Rafael
• dc.contributor.author Virgili, Núria
• dc.contributor.author Soriano-Mas, Carles
• dc.contributor.author Jiménez Murcia, Susana
• dc.contributor.author Torre Fornell, Rafael de la
• dc.contributor.author Fernández Aranda, Fernando
• dc.date.accessioned 2023-07-11T06:12:06Z
• dc.date.available 2023-07-11T06:12:06Z
• dc.date.issued 2023
• dc.description.abstract Background: Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) play a pivotal role in stimulating motivational behavior toward food and energy metabolism. Aberrant functioning of the endocannabinoid system has been observed in extreme weight conditions (EWCs), suggesting it may influence pathophysiology. Then, we aimed to analyze fasting AEA and 2-AG plasma concentrations among individuals with EWC (i.e., anorexia nervosa [AN] and obesity with and without eating disorders [EDs]) compared with healthy controls (HCs), and its association with clinical variables and body mass index (BMI). Methods: The sample included 113 adult women. Fifty-seven belonged to the obesity group, 37 without EDs (OB-ED) and 20 with ED (OB+ED classified within the binge spectrum disorders), 27 individuals from the AN group, and 29 from the HC group. Peripheral blood samples, several clinical variables, and BMI were evaluated. Results: Unlike 2-AG, AEA concentrations showed significant differences between groups (p < 0.001). Increased AEA was observed in the OB-ED and OB+ED compared with both HC and AN group, respectively. Likewise, AEA was differentially associated with emotional dysregulation, general psychopathology, food addiction, and BMI in all clinical groups. Conclusions: These results support the interaction between biological and clinical factors contributing to delineating vulnerability pathways in EWC that could help fit personalized therapeutic approaches.
• dc.description.sponsorship We thank CERCA Programme / Generalitat de Cataluny a for institutional support. This manuscript and research were supported by grants from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031), Ministerio de Ciencia e Innovación (PDI2021-124887OB-I00), Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and cofounded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. CIBER Obn, CIBERSAM, and CIBERDEM are initiatives of ISCIII. Additional funding was received by AGAUR- Generalitat de Catalunya (2021-SGR-00824 and 2021 SGR 00253) and European Union’s Horizon 2020 research and innovation program under Grant agreement no. 728018 (H2020-SFS-2016-2, Eat2beNice), no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multi morbidity in Europe) and no. 101080219 (eprObes). This study has also been funded by Instituto de Salud Carlos III through the grant CM21/00172 (IB) (Co-funded by European Social Fund. ESF investing in your future). RG is supported by the Catalan Institution for Research and Advanced Studies (ICREA-Academia, 2021-Programme). The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.
• dc.format.mimetype application/pdf
• dc.identifier.citation Baenas I, Miranda-Olivos R, Granero R, Solé-Morata N, Sánchez I, Pastor A, Del Pino-Gutiérrez A, Codina E, Tinahones FJ, Fernández-Formoso JA, Vilarrasa N, Guerrero-Pérez F, Lopez-Urdiales R, Virgili N, Soriano-Mas C, Jiménez-Murcia S, de la Torre R, Fernández-Aranda F. Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity. Eur Psychiatry. 2023 May 31;66(1):e49. DOI: 10.1192/j.eurpsy.2023.2411
• dc.identifier.doi http://dx.doi.org/10.1192/j.eurpsy.2023.2411
• dc.identifier.issn 0924-9338
• dc.identifier.uri http://hdl.handle.net/10230/57525
• dc.language.iso eng
• dc.publisher Cambridge University Press
• dc.relation.ispartof Eur Psychiatry. 2023 May 31;66(1):e49
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/728018
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/847879
• dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101080219
• dc.rights © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0
• dc.subject.keyword 2-arachidonoylglycerol
• dc.subject.keyword Anandamide
• dc.subject.keyword Eating disorders
• dc.subject.keyword Endocannabinoids
• dc.subject.keyword Obesity
• dc.title Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion